Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of T Cell Vaccination in HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. CD4 cell counts -from 150 to 450/mm3 and stable for at least 12 months, and treatment with HAART for at least 6 months.~2. Positive cell proliferation assay to CD4 molecule~3. Low HIV viral load (\<400 - 5000 copies/ml) for at least 12 months~4. No change of antiretroviral treatment for at least 6 months~5. Signed informed consent~Exclusion Criteria:~1. Concomitant immunosuppressive or antineoplastic treatment as well as chronic systemic glucocorticoid therapy.~2. Pregnancy and women without any efficacious contraception.~3. Clinically relevant liver disease (AST and/or ALT \>2,5x upper limit of normal range, or total bilirubin \> 3,5 mg/dl).~4. Serum creatinine \>1,8mg/dl or creatinine clearance \<30ml/min.~5. Patients who cannot fully understand the treatment protocol or are unable to sign the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Vaccination (Type: EXPERIMENTAL): One arm of open label T cell vaccination in which all participants will receive the T cell vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).